Product image of Memantine Mylan (Memantine Hydrochloride) supplied by GNH India

Memantine Mylan

Active Ingredient:
Memantine Hydrochloride
Origin:
EU

Memantine Mylan (Memantine Hydrochloride)

Memantine Hydrochloride, the active ingredient in Memantine Mylan, is a NMDA receptor antagonist presented as an oral formulation for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients and may help improve cognitive function and daily living activities.

GNH India supplies Memantine Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring reliable delivery and compliance with local regulatory requirements throughout.

Manufacturer / TM Owner

Mylan Pharmaceuticals Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Memantine Mylan is employed in the therapeutic approach to neurodegenerative disorders characterized by excessive activation of NMDA receptors, which leads to neuronal injury. Its principal and approved clinical use is in Alzheimer’s disease, where it may help maintain cognitive function and daily activities.
  • Alzheimer’s disease: improves cognition and functional abilities in patients with moderate to severe disease.

How It Works

  • Memantine Hydrochloride acts as a non‑competitive antagonist at the N‑methyl‑D‑aspartate (NMDA) receptor. By binding to the receptor‑associated ion channel with moderate affinity and rapid off‑rate, it blocks excessive calcium influx caused by prolonged glutamate stimulation, thereby reducing excitotoxic neuronal damage while preserving normal synaptic transmission. This modulation helps to stabilize neuronal activity without completely inhibiting physiological glutamate signaling, which is essential for learning and memory processes.

Side Effects

Memantine Mylan may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Dizziness: sensation of light‑headedness or unsteadiness.
  • Headache: mild to moderate intensity.
  • Constipation: reduced bowel movements.
  • Fatigue: feeling of tiredness.
  • Insomnia: difficulty falling or staying asleep.
  • Confusion: transient disorientation.

Serious or Rare Side Effects

  • Seizures: occurrence of convulsive episodes.
  • Hallucinations: visual or auditory perceptual disturbances.
  • Cardiac arrhythmia: irregular heart rhythm.
  • Severe skin reactions: such as Stevens‑Johnson syndrome.
  • Elevated liver enzymes: indicating possible hepatic stress.
  • Suicidal thoughts: emergence of depressive ideation.

Precautions & Warnings

When prescribing Memantine Mylan, clinicians should consider several precautionary measures to ensure patient safety.

  • Renal impairment: adjust dose or monitor renal function.
  • Hepatic impairment: use with caution and monitor liver tests.
  • History of seizures: assess risk and observe for seizure activity.
  • Elderly patients: start at low dose and monitor for confusion.
  • Concomitant NMDA antagonists: avoid combined use due to additive effects.
  • Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Avoid Interactions

Memantine Mylan can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

  • Amantadine: combined NMDA antagonism may increase neurotoxicity.
  • Ketamine: additive CNS depression and dissociative effects.
  • Dextromethorphan: heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

  • NSAIDs: may increase risk of renal dysfunction.
  • Anticholinergic agents: may reduce cognitive benefits of memantine.

Frequently Asked Questions

Memantine Mylan is prescribed for the symptomatic treatment of moderate to severe Alzheimer’s disease. By modulating glutamate activity, it may help preserve cognitive function and daily living abilities in adult patients diagnosed with this neurodegenerative condition.

Memantine Hydrochloride acts as a non‑competitive antagonist at NMDA receptors. It blocks excessive calcium entry caused by prolonged glutamate stimulation, reducing excitotoxic neuronal injury while allowing normal synaptic transmission essential for learning and memory.

The appropriate dose of Memantine Mylan is determined by the prescribing clinician based on the patient’s clinical status, renal function, and tolerability. Dosage adjustments are individualized, and patients should follow the prescriber’s specific instructions.

Safety data for Memantine Mylan in pregnancy and lactation are limited. Healthcare providers usually weigh potential benefits against unknown risks, and the drug should only be used if clearly needed and after consulting a specialist.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Memantine Mylan. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine Mylan belongs to the NMDA‑receptor antagonist class, whereas drugs such as donepezil, rivastigmine and galantamine are cholinesterase inhibitors. Memantine targets excitotoxic pathways, often used in later disease stages, and may be combined with a cholinesterase inhibitor for additive benefit.

Memantine Mylan should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Memantine Mylan is taken orally, usually with or without food, as directed by the prescriber. Tablets are swallowed whole with a glass of water, and the dosing schedule is individualized based on clinical response and tolerability.

Serious adverse events include seizures, hallucinations, cardiac arrhythmias, severe skin reactions such as Stevens‑Johnson syndrome, elevated liver enzymes, and emergence of suicidal thoughts. Patients should be monitored closely for any of these symptoms and seek medical attention promptly if they occur.

Memantine Mylan is contraindicated in patients with known hypersensitivity to memantine or any excipients in the formulation. Caution is advised for individuals with severe renal impairment, uncontrolled epilepsy, or those taking other NMDA‑receptor antagonists, as combined use may increase toxicity.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Memantine Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT